261901-57-9 - Names and Identifiers
261901-57-9 - Physico-chemical Properties
Molecular Formula | C18H28N2O3SHCl
|
Solubility | Soluble in water (100 mM ), DMSO (100 mM ), phosphate buffered saline (5 mM ), and |
Appearance | powder |
Storage Condition | 2-8°C |
Use | A selective and potent SR-7 antagonist. |
In vitro study | SB-269970 inhibits 5-CT stimulated adenylate cyclase activity on guinea pig hippocampal cell membrane. SB-269970 (0.03 μm, 0.1 μm, 0.3 μm and 1 μm) will shift the 5-CT concentration response curve to the right, this effect correlated with the SB-269970 concentration but did not change significantly for the 5-CT maximal response. SB-269970 (1 M) alone has little effect on the efflux of 5-HT. SB-269970 inhibited the activity of 5-CT-stimulated adenylate cyclase on the membrane of guinea pig hippocampus. SB-269970 (0.03 μm, 0.1 μm, 0.3 μm and 1 μm) will shift the 5-CT concentration response curve to the right, this effect correlated with the SB-269970 concentration but did not change significantly for the 5-CT maximal response. SB-269970 (1 M) alone has little effect on the efflux of 5-HT. |
In vivo study | SB-269970 (10 mg/kg and 30 mg/kg) can significantly reduce the effect of ampetamine by 25 and 27%, respectively, and can block the effect of ketamine by 38% (10 mg/kg). And 30% (30 mg/kg). SB-269970 significantly attenuated ampetamine-induced ADHD in wild-type mice but had no effect on 5-HT7 knockout mice. Systemic SB-269970 (30 mg/kg) treatment significantly reversed the disruption of PPI caused by ampetamine but did not increase the amount of PPI itself compared to the control group. SB-269970 can significantly reverse the MK-801-induced defect but has no effect on the scopolamin-induced. SB-269970 normalizes MK-801 induced glutamate but has no effect on the release of dopamine in the cortex. SB-269970 (0.5 or 1 mg/kg) showed specific anti-Anxiety-like effects in the rat Vogel drinking water test, the elevated plus maze test and the mouse four-plate test. In addition, SB-269970 (5 or 10 mg/kg) had antidepressant effects in forced swimming and tail suspension experiments in mice. 0.3, 1 and 3 μg SB-269970 had anti-collision effects that were lower than diazepa (40 μg), while 3 and 10 μg SB-269970 had anti-collision effects with imipramine (0.1 μg). SB-269970 (10 mg/kg and 30 mg/kg) can significantly reduce the effect of ampetamine by 25 and 27%, respectively, the effect of ketamine was blocked by 38% (10 mg/kg) and 30% (30 mg/kg). SB-269970 significantly attenuated ampetamine-induced ADHD in wild-type mice but had no effect on 5-HT7 knockout mice. Compared with the control group, the systemic administration was SB-269970 (30 mg/kg) treatment can significantly reverse the destruction of PPI caused by AMP, but does not increase the content of PPI itself. SB-269970 can significantly reverse the MK-801-induced defect but has no effect on the scopolamin-induced. SB-269970 normalizes MK-801 induced glutamate but has no effect on the release of dopamine in the cortex. SB-269970 (0.5 or 1 mg/kg) showed specific anti-Anxiety-like effects in the rat Vogel drinking water test, the elevated plus maze test and the mouse four-plate test. In addition, SB-269970 (5 or 10 mg/kg) had antidepressant effects in forced swimming and tail suspension experiments in mice. 0.3, 1 and 3 μg SB-269970 had anti-collision effects that were lower than diazepa (40 μg), while 3 and 10 μg SB-269970 had anti-collision effects with imipramine (0.1 μg). Compared with the obvious anti-immobility effect |
261901-57-9 - Risk and Safety
261901-57-9 - Introduction
SB269970 HCl is a SB-269970 hydrochloride form and is a 5-HT7 receptor antagonist with pKi of 8.3, which is more than 50 times more selective than acting on other receptors.
Last Update:2022-10-16 17:41:35
261901-57-9 - Introduction
SB269970 is a chemical that is a selective serotonin 1A(5-HT1A) receptor antagonist. 5-HT1A is a receptor in the brain that regulates pneumatic function, and SB269970 HCl can bind to this receptor and block its function.
SB269970 HCl has a certain application in the field of medicine. Because its antagonistic effect can affect the activity of 5-HT1A receptor in the brain, it can be used to study the function and mechanism of 5-HT1A receptor in the nervous system. In addition, SB269970 HCl is also being studied for the treatment of certain neurological disorders and mental disorders.
The preparation method of SB269970 HCl is obtained by chemical synthesis. Specifically, it can be prepared by synthesizing intermediates and performing subsequent chemical reactions.
Regarding safety information, SB269970 HCl is a chemical substance, and some safety measures need to be paid attention to when using and handling. It may be irritating to the eyes and skin, so direct contact should be avoided when in contact. Wear appropriate protective gloves, glasses, and laboratory ventilation during use and handling. Also, follow proper laboratory procedures and avoid ingestion, inhalation, or exposure to SB269970 HCl. In case of accidental contact or inhalation, please rinse with water immediately, and timely medical treatment.
Last Update:2024-04-09 21:11:58